EP0716696A1
(en)
|
1993-09-03 |
1996-06-19 |
Immulogic Pharmaceutical Corporation |
Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
|
WO1995007096A1
(en)
|
1993-09-06 |
1995-03-16 |
La Trobe University |
Treatment of autoimmune disease
|
US6251396B1
(en)
|
1994-11-18 |
2001-06-26 |
Neurocrine Biosciences, Inc. |
Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
|
CA2250361A1
(en)
*
|
1996-03-28 |
1997-10-02 |
Barbara Wallner |
Myelin oligodendrocyte glycoprotein peptides and uses thereof
|
SE9703287D0
(sv)
|
1997-09-11 |
1997-09-11 |
Astra Ab |
Peptides
|
ATE308244T1
(de)
|
1999-03-12 |
2005-11-15 |
Univ Leland Stanford Junior |
Dna-impfung zur behandlung von autoimmunerkrankungen
|
IL132611A0
(en)
|
1999-10-27 |
2001-03-19 |
Yeda Res & Dev |
Synthetic genes and polypeptides and pharmaceutical compositions comprising them
|
EP1267909B1
(en)
|
2000-03-29 |
2010-07-28 |
The Ohio State University Research Foundation |
Methods of blocking tissue destruction by autoreactive t cells
|
PL215187B1
(pl)
|
2000-08-21 |
2013-11-29 |
Apitope Technology Bristol Ltd |
Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
HUP0401863A3
(en)
|
2001-10-03 |
2012-09-28 |
Harvard College |
Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
|
CA2614171C
(en)
|
2001-10-03 |
2012-04-24 |
President And Fellows Of Harvard College |
Copolymers for suppression of autoimmune diseases, and methods of use
|
IL146016A0
(en)
|
2001-10-17 |
2002-07-25 |
Yeda Res & Dev |
Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
|
US7700572B2
(en)
|
2001-11-02 |
2010-04-20 |
Giuliani International, Ltd. |
SMAD7 inhibitors for the treatment of CNS diseases
|
NZ537816A
(en)
|
2002-08-08 |
2007-06-29 |
Baylor College Medicine |
An autologous T cell vaccine for the treatment of multiple sclerosis
|
CA2499843A1
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
EP1625148B1
(en)
|
2003-05-21 |
2012-09-26 |
Biotech Tools S.A. |
Peptide complex
|
EP2783699A1
(en)
|
2003-09-05 |
2014-10-01 |
Oregon Health & Science University |
Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
|
AU2011202900B2
(en)
|
2003-09-05 |
2012-08-02 |
Oregon Health & Science University |
Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
|
WO2006057003A2
(en)
|
2004-11-29 |
2006-06-01 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
AU2012201067A1
(en)
|
2005-03-14 |
2012-03-15 |
B.G. Negev Technologies And Applications Ltd. |
Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
|
IL185932A
(en)
|
2005-03-14 |
2014-02-27 |
Yeda Res & Dev |
Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis
|
US20080279878A1
(en)
|
2005-03-14 |
2008-11-13 |
B.G. Negev Technologies And Applications Ltd. |
Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis
|
US8202835B2
(en)
|
2005-06-17 |
2012-06-19 |
Yitzchak Hillman |
Disease treatment via antimicrobial peptides or their inhibitors
|
JP5312028B2
(ja)
|
2005-09-28 |
2013-10-09 |
サイトス バイオテクノロジー アーゲー |
インターロイキン−1コンジュゲート及びその使用
|
EP2338517A1
(en)
|
2005-11-14 |
2011-06-29 |
Ribomic Inc |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
AU2006318791B2
(en)
|
2005-11-17 |
2012-07-12 |
Case Western Reserve University |
Multipotent neural stem cells
|
US7803364B2
(en)
|
2005-11-17 |
2010-09-28 |
The Cleveland Clinic Foundation |
Multipotent neural stem cells
|
US20090304726A1
(en)
|
2006-02-15 |
2009-12-10 |
Ramot At Tel Aviv University Ltd. |
Viral display vehicles for treating multiple sclerosis
|
EP1987066B1
(en)
|
2006-02-22 |
2010-12-29 |
University of Zürich |
Methods for treating demyelinating diseases
|
DK2420833T3
(en)
|
2006-05-05 |
2015-12-07 |
Opexa Therapeutics |
T-cell vaccine
|
AU2012202713B2
(en)
|
2006-05-31 |
2015-04-09 |
Lpath, Inc. |
Immune-derived moieties reactive against lysophosphatidic acid
|
AU2012202776A1
(en)
|
2006-05-31 |
2012-05-31 |
Lpath, Inc. |
Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
|
WO2007149982A2
(en)
|
2006-06-22 |
2007-12-27 |
The Brigham And Women's Hospital, Inc. |
Diagnosis of autoimmune disease
|
AU2007308838B2
(en)
|
2006-10-25 |
2014-03-13 |
Revalesio Corporation |
Mixing device and output fluids of same
|
WO2008070344A2
(en)
|
2006-10-27 |
2008-06-12 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
US8188218B2
(en)
|
2006-10-27 |
2012-05-29 |
University Of Kansas |
Bi-functional peptides for multiple sclerosis treatment and diagnosis
|
WO2008149354A2
(en)
|
2007-06-04 |
2008-12-11 |
Rappaport Family Institute For Research In The Medical Sciences |
Agents for the treatment of inflammatory diseases and methods of using same
|
EP2050814A1
(en)
|
2007-10-17 |
2009-04-22 |
Txcell |
Compositions for treating multiple sclerosis
|
US20090227018A1
(en)
|
2007-10-25 |
2009-09-10 |
Revalesio Corporation |
Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
|
PT2211892E
(pt)
|
2007-10-31 |
2011-10-18 |
Apitope Technology Bristol Ltd |
Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas
|
CA2715536C
(en)
|
2008-02-14 |
2018-01-16 |
Life Sciences Research Partners Vzw |
Cd4+ t-cells with cytolytic properties
|
EP2355660A4
(en)
|
2008-10-13 |
2012-05-02 |
Biovista Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
|
BRPI0920201A2
(pt)
|
2008-10-22 |
2019-09-10 |
Revalesio Corp |
composicoes e metodos para tratar condicoes mediadas por linfopoetina do estroma timico(tslp)
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010055510A2
(en)
|
2008-11-12 |
2010-05-20 |
Yeda Research And Development Co. Ltd. |
Diagnosis of multiple sclerosis
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
MX2011011333A
(es)
|
2009-04-27 |
2011-11-18 |
Revalesio Corp |
Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.
|
US8703711B2
(en)
|
2009-06-09 |
2014-04-22 |
Val-Chum, Limited Partnership |
Ninjurin-1 modulation and uses thereof
|
US8293468B2
(en)
|
2009-06-10 |
2012-10-23 |
Centre Hospitalier De L'université De Montréal |
MCAM modulation and uses thereof
|
EP2473523A2
(en)
|
2009-08-31 |
2012-07-11 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
WO2011071059A1
(ja)
|
2009-12-09 |
2011-06-16 |
国立大学法人大阪大学 |
T細胞活性化阻害剤、これを含有する医薬組成物およびt細胞活性化阻害物質のスクリーニング方法
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
US20110189178A1
(en)
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
PL217128B1
(pl)
|
2010-08-02 |
2014-06-30 |
Inst Biochemii I Biofizyki Polskiej Akademii Nauk |
Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
|
EP2600885A2
(en)
|
2010-08-04 |
2013-06-12 |
Ramot at Tel Aviv University, Ltd. |
Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
|
EP2600878A4
(en)
|
2010-08-04 |
2014-06-11 |
Univ Duke |
REGULATORY B-CELLS AND ITS USES
|
EP2603202A4
(en)
|
2010-08-12 |
2016-06-01 |
Revalesio Corp |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
|
WO2012031258A1
(en)
|
2010-09-03 |
2012-03-08 |
Oregon Health & Science University |
Recombinant t-cell receptor ligands with covalently bound peptides
|
EP2617435A4
(en)
|
2010-09-16 |
2014-03-12 |
Univ Osaka |
THERAPEUTICS AND PROPHYLACTIC AGENTS FOR COMPOSITIONS OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES, ALLERGIC DISEASES AND ORGAN TRANSPLANTS
|
CA2809360A1
(en)
|
2010-09-27 |
2012-04-05 |
China Agricultural University |
Combined antigen and dna vaccine for preventing and treating autoimmune diseases
|
WO2012045324A1
(en)
|
2010-10-07 |
2012-04-12 |
Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh |
Method for detecting a parkinson's disease and test system
|
EP2632955A1
(en)
|
2010-10-26 |
2013-09-04 |
Technion Research & Development Foundation Ltd. |
Antibodies which bind soluble t-cell receptor ligands
|
WO2012092485A1
(en)
|
2010-12-31 |
2012-07-05 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
EP2667888A4
(en)
|
2011-01-28 |
2015-11-11 |
Univ Oregon Health & Science |
LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
US8685404B2
(en)
|
2011-01-31 |
2014-04-01 |
Oregon Health & Science University |
Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
|
RS58114B1
(sr)
|
2011-03-01 |
2019-02-28 |
Pharnext |
Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
|
JP5878447B2
(ja)
|
2012-09-12 |
2016-03-08 |
富士フイルム株式会社 |
ベースメイク化粧料
|
GB201300684D0
(en)
|
2013-01-15 |
2013-02-27 |
Apitope Int Nv |
Peptide
|